Aim: Use of Surface Mould Brachytherapy in the treatment of skin and oral malignancies at our institution. Background: SMB offers a good therapeutic ratio helping in dose escalation of irradiationand higher Biologically equivalent doses. In this study, we share our institutional experience with SMB in different types of cancers. Materials and Methods: 15 Patients with oral, skin, and penile malignancies treated with SMB were analyzed from Jan 2019 to Sept 2023. Treatment was delivered using HDR Co 60 source with a customized mouldto a median dose of 48Gy in the radical setting and 15Gy as a boost with 2.5-3Gy/# twice a day. The treatment-related toxicities and response were noted. Results: 15 patients with various malignancies were evaluated. Eight patients received SMB alone while 7 patients external beam radiotherapy with SMB Boost. A Complete: Partial response ratio of about 80:20 was achieved. There were 3 local failures all in hard Palate patients. The acute toxicity outcomes were as follows - 12 patients of Grade 1 and 3 patients of Grade 2 toxicities. Late toxicities reported were Grade 1 in six patients, Grade 2 in 5 patients, and Grade 3 in one patient. Conclusion: Surface mould brachytherapy provides maximum local tumor control, is well-tolerated, and is a non-invasive, outpatient procedure for treatment in both radical settings and as a boost. It results in organ and function preservation and is a good alternative option for patients who are unwilling for surgery and who present with comorbidities.